Loading clinical trials...
Loading clinical trials...
Extension to a Multi-Center, Randomized, Crossover, Open Label, Dose Finding Study to Compare the Safety, Efficacy, and Pharmacokinetics/Pharmacodynamics (PK/PD) Relationship of Multiple Doses of Pasireotide (SOM230) (200, 400, and 600 μg Bid) and Doses of Open Label Sandostatin® (SMS) (100 μg Tid) in Acromegalic Patients
Conditions
Interventions
Pasireotide
Locations
10
United States
Cedars Sinai Medical Center Dept. of Pituitary Ctr.
Los Angeles, California, United States
University of Michigan Health System StudyCoordinatorCSOM230B2201E1
Ann Arbor, Michigan, United States
NYU / VA Medical Center
New York, New York, United States
Novartis Investigative Site
Woolloongabba, Queensland, Australia
Novartis Investigative Site
Edegem, Belgium
Novartis Investigative Site
Toulouse Cédex 4, France
Start Date
August 24, 2004
Primary Completion Date
December 6, 2013
Completion Date
December 6, 2013
Last Updated
September 5, 2021
NCT00001595
NCT04837040
NCT04125836
NCT06253897
NCT02611336
NCT05184231
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions